CANTON, Mass., Sept. 4, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data from the clinical development program for Xtampza™ ER, an abuse-deterrent, extended-release oral formulation of oxycodone, at PAINWeek 2015, taking place September 8-12, 2015 at The Cosmopolitan in Las Vegas.
The five posters include results from a series of studies that evaluate the abuse-deterrent properties of Xtampza ER, conducted in accordance with guidance on abuse-deterrent opioids from the U.S. Food and Drug Administration (FDA), as well as data from Collegium's Phase 3 clinical trial.
"These data further support the development of new abuse-deterrent technologies that may help people suffering with chronic pain to receive effective treatment, while potentially reducing the risk of misuse and abuse," said Michael Heffernan, CEO of Collegium. "We are committed to advancing the development of our DETERx® technology platform and look forward to sharing these findings with the scientific community."
The posters to be presented at the Scientific Session reception on Thursday, September 10 at 6:30pm – 8:30pm include:
- Abuse-Deterrent Properties of Oxycodone DETERx, an Extended-release Formulation for Chronic Pain Management
- In Vitro Studies Characterizing Oxycodone DETERx: An Abuse-deterrent, Extended-release Formulation
- Oral and Intranasal Human Abuse Potential of Oxycodone DETERx: An Abuse-deterrent, Extended-release Formulation
- Sprinkle Administration of Oxycodone DETERx: An Abuse-deterrent, Extended-release Formulation
- Evaluation of the Durability of Pain Relief of Oxycodone DETERx: An Extended-release, Abuse-deterrent Formulation throughout its 12-hour Dosing Interval
About Xtampza ER
Collegium's lead product candidate, Xtampza™ ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone, in development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Collegium developed Xtampza ER using its proprietary DETERx® technology platform to address common methods of abuse, including chewing, crushing and/or dissolving, and then taking it orally or snorting or injecting.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. The new drug application, or NDA, submission for Xtampza ER, the Company's lead product candidate, was accepted for review by the FDA on February 10, 2015. The FDA set a Prescription Drug User Fee Act, or PDUFA, goal date of October 12, 2015 for completion of its review of the Xtampza ER NDA.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that we will obtain approval for Xtampza ER or any of our other product candidates from the U.S. Food and Drug Administration ("FDA") or foreign regulatory authorities; even if Xtampza ER is approved, we may not be able to obtain the label claims that we are seeking from the FDA. Furthermore, we are subject to patent infringement litigation relating to Xtampza ER and may, in the future, be subject to additional litigation relating to our other product candidates, which may be expensive to defend and delay the commercialization of Xtampza ER or our other product candidates. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: our ability to commercialize our product candidates; the size and growth potential of the markets for our product candidates, and our ability to service those markets; our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of our product candidates; the success, cost and timing of our product development activities, studies and clinical trials; the success of competing products that are or become available; and our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for our product candidates. These and other risks are described under the heading "Risk Factors" in a Current Report on Form 8-K, which was filed with the Securities and Exchange Commission ("SEC") on June 19, 2015, and those risks described from time to time in other reports which we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CONTACT: Douglas Carlson Vice President, Corporate Development firstname.lastname@example.org